Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 3, 2026, 7:30 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 52 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Mildly Impaired Renal Function Clear all
Terminated Phase 2 Interventional

Phase IIa Study of ALLN-346 (Engineered Urate Oxidase) in Subjects With Hyperuricemia, Gout and Chronic Kidney Disease

NCT04987294
View directory record Official record
Conditions
Hyperuricemia, Gout, Chronic Kidney Diseases
Interventions
ALLN-346, Placebo
Drug
Lead sponsor
Allena Pharmaceuticals
Industry
Eligibility
18 Years to 70 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
17
States / cities
Birmingham, Alabama • Muscle Shoals, Alabama • Sheffield, Alabama + 12 more
Source: ClinicalTrials.gov public record
Updated Jun 22, 2023 · Synced Sep 3, 2026, 7:30 AM EDT
Completed Phase 1 Interventional

Study to Evaluate TRV120027 on Renal Pharmacodynamics in Patients With Heart Failure and Renal Dysfunction

NCT01444872
View directory record Official record
Conditions
Heart Failure, Kidney Disease
Interventions
TRV120027, Normal Saline
Drug
Lead sponsor
Trevena Inc.
Industry
Eligibility
18 Years to 74 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
4
States / cities
Orlando, Florida • Minneapolis, Minnesota • Durham, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 26, 2012 · Synced Sep 3, 2026, 7:30 AM EDT
Completed Phase 3 Interventional Results available

Cobicistat-containing Highly Active Antiretroviral Regimens in HIV-1 Infected Patients With Mild to Moderate Renal Impairment

NCT01363011
View directory record Official record
Conditions
Acquired Immunodeficiency Syndrome, HIV Infections
Interventions
E/C/F/TDF, COBI, ATV, DRV, NRTI
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
34
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Beverly Hills, California + 24 more
Source: ClinicalTrials.gov public record
Updated May 1, 2016 · Synced Sep 3, 2026, 7:30 AM EDT
Terminated Not applicable Interventional Results available

Mild Hypothermia and Acute Kidney Injury in Liver Transplantation

NCT03534141
View directory record Official record
Conditions
Cirrhosis, End Stage Liver Disease, Acute Kidney Injury, Liver Transplant; Complications, Chronic Kidney Diseases, Hepatitis c, Hepatitis B, NASH - Nonalcoholic Steatohepatitis, Alcoholic Cirrhosis, Hepatocellular Carcinoma
Interventions
Esophageal cooling/warming device, Mild hypothermia, Normothermia
Device · Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
175 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
3
States / cities
San Francisco, California • Aurora, Colorado • Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 15, 2025 · Synced Sep 3, 2026, 7:30 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate Pharmacokinetic and Safety Trial of Emraclidine in Participants With Renal Impairment Compared With Participants With Normal Renal Function

NCT05940402
View directory record Official record
Conditions
Renal Impairment
Interventions
Emraclidine
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 75 Years
Enrollment
58 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
5
States / cities
Tustin, California • Miami, Florida • Orlando, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 3, 2025 · Synced Sep 3, 2026, 7:30 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Evaluate Pharmacokinetics of ITCA 650 in Subjects With Renal Impairment Compared to Normal Subjects

NCT02320045
View directory record Official record
Conditions
Renal Insufficiency
Interventions
ITCA 650 (Exenatide in osmotic mini pump)
Drug
Lead sponsor
Intarcia Therapeutics
Industry
Eligibility
25 Years to 80 Years
Enrollment
38 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 2, 2016 · Synced Sep 3, 2026, 7:30 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Open-Label, Single-Dose Study to Evaluate the Safety and PK of DIC075V in Subjects With Renal Insufficiency and Hepatic Impairment Compared to Healthy Subjects and Evaluate the Safety and Pharmacokinetics of HPβCD When Administered in DIC075V Compared to Sporanox® in Healthy Subjects

NCT00805090
View directory record Official record
Conditions
Renal Insufficiency, Chronic, Hepatic Insufficiency, Healthy
Interventions
Sporanox, Diclofenac Sodium
Drug
Lead sponsor
Javelin Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
37 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
3
States / cities
Orlando, Florida • Minneapolis, Minnesota • Knoxville, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 29, 2009 · Synced Sep 3, 2026, 7:30 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

An Investigational Study of ESK-001 in Participants With Normal Renal Function and Participants With Mild, Moderate, and Severe Impaired Renal Function

NCT06962774
View directory record Official record
Conditions
Renal Impairment
Interventions
ESK-001
Drug
Lead sponsor
Alumis Inc
Industry
Eligibility
18 Years to 75 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
4
States / cities
Miami, Florida • Miami Lakes, Florida • Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Dec 9, 2025 · Synced Sep 3, 2026, 7:30 AM EDT
Terminated Phase 1 Interventional

To Evaluate Safety and Pharmacokinetics of Belinostat in Patients Who Have Mild, Moderate and Severe Renal Impairment.

NCT02679131
View directory record Official record
Conditions
Relapsed/Refractory Solid Tumors/Hematological Malignancies
Interventions
Belinostat
Drug
Lead sponsor
Acrotech Biopharma Inc.
Industry
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
2
States / cities
Whittier, California • Canton, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 19, 2019 · Synced Sep 3, 2026, 7:30 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Safety of Experimental Medication BMS986165 in Participants With Normal Kidney Function and Participants With Mild to End-Stage Kidney Disease.

NCT03890770
View directory record Official record
Conditions
Renal Impairment, Healthy Volunteer
Interventions
BMS-986165
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 70 Years
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Mar 11, 2021 · Synced Sep 3, 2026, 7:30 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetics and Safety of Fevipiprant in Patients With Renal Impairment Compared to Matched Healthy Subjects

NCT03087942
View directory record Official record
Conditions
Renal Insufficiency
Interventions
QAW039, QAW39A, QAW39A2107
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Dec 10, 2020 · Synced Sep 3, 2026, 7:30 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetics of LCQ908 in Patients With Renal Impairment

NCT01558323
View directory record Official record
Conditions
Renal Impairment
Interventions
LCQ908
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
58 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
2
States / cities
Orlando, Florida • Knoxville, Tennessee
Source: ClinicalTrials.gov public record
Updated Dec 18, 2020 · Synced Sep 3, 2026, 7:30 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetics of Elinogrel in Healthy Volunteers and Patients With Mild, Moderate, and Severe Renal Impairment

NCT00984113
View directory record Official record
Conditions
Renal Impairment
Interventions
Elinogrel
Drug
Lead sponsor
Portola Pharmaceuticals
Industry
Eligibility
18 Years to 80 Years
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
2
States / cities
Minneapolis, Minnesota • Knoxville, Tennessee
Source: ClinicalTrials.gov public record
Updated Aug 3, 2023 · Synced Sep 3, 2026, 7:30 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Compare Conivaptan Pharmacokinetics in Subjects With Mild & Moderate Kidney Function Impairment to Subjects With Normal Kidney Function

NCT00887627
View directory record Official record
Conditions
Kidney Diseases, Hyponatremia
Interventions
conivaptan hydrochloride
Drug
Lead sponsor
Cumberland Pharmaceuticals
Industry
Eligibility
18 Years to 70 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
1
States / cities
Anaheim, California
Source: ClinicalTrials.gov public record
Updated May 1, 2014 · Synced Sep 3, 2026, 7:30 AM EDT
Terminated Phase 1 Interventional Results available

A Study to Measure the Amount of Study Medicine in Blood in Adult Participants With COVID-19 and Severe Kidney Disease

NCT05487040
View directory record Official record
Conditions
COVID-19
Interventions
PF-07321332 (nirmatrelvir)/ritonavir
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
52
States / cities
Huntsville, Alabama • Granada Hills, California • Inglewood, California + 26 more
Source: ClinicalTrials.gov public record
Updated Sep 22, 2024 · Synced Sep 3, 2026, 7:30 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetics, Safety and Tolerability of AGO178C in Subjects With Renal Deficiencies Compared With Healthy Subjects

NCT01459250
View directory record Official record
Conditions
Renal Impairment
Interventions
AGO178C
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 79 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2011
U.S. locations
4
States / cities
Miami, Florida • Orlando, Florida • Minneapolis, Minnesota + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 7, 2020 · Synced Sep 3, 2026, 7:30 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Pharmacokinetics of Entinostat in Adult Subjects With Normal and Impaired Renal Function

NCT03192111
View directory record Official record
Conditions
Renal Impairment, Healthy Volunteer
Interventions
Entinostat
Drug
Lead sponsor
Syndax Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
3
States / cities
Miami, Florida • Orlando, Florida • Knoxville, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 12, 2018 · Synced Sep 3, 2026, 7:30 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of the Effects of Renal Impairment on the Pharmacokinetics and Tolerability of Eliglustat Tartrate

NCT02536937
View directory record Official record
Conditions
Gaucher Disease
Interventions
eliglustat
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 79 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
3
States / cities
Miami, Florida • Saint Paul, Minnesota • Knoxville, Tennessee
Source: ClinicalTrials.gov public record
Updated Mar 7, 2017 · Synced Sep 3, 2026, 7:30 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetic Study of BMS-914143 in Participants With Normal Renal Function and Mild, Moderate, Severe and End-stage Renal Dysfunction

NCT01708889
View directory record Official record
Conditions
Chronic Hepatitis B Virus Infection, Chronic Hepatitis C Virus Infection
Interventions
BMS-914143 (Peginterferon Lambda-1a)
Biological
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 75 Years
Enrollment
43 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
3
States / cities
Miami, Florida • Orlando, Florida • Knoxville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jun 4, 2013 · Synced Sep 3, 2026, 7:30 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetic Study of Vildagliptin in Patients With Renal Impairment

NCT00567047
View directory record Official record
Conditions
Type-2 Diabetes
Interventions
vildagliptin
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years to 85 Years
Enrollment
96 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2007
U.S. locations
5
States / cities
Miami, Florida • Orlando, Florida • Minneapolis, Minnesota + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 24, 2009 · Synced Sep 3, 2026, 7:30 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

A Study of the Pharmacokinetics and Safety of Varespladib in Subjects With Normal or Impaired Renal Function

NCT01359579
View directory record Official record
Conditions
Renal Impairment
Interventions
varespladib methyl
Drug
Lead sponsor
Anthera Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
3
States / cities
Orlando, Florida • Minneapolis, Minnesota • Knoxville, Tennessee
Source: ClinicalTrials.gov public record
Updated Mar 19, 2012 · Synced Sep 3, 2026, 7:30 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

Comparative Study of Quinine Sulfate in Healthy Patients and in Patients With Renal Impairment

NCT00785551
View directory record Official record
Conditions
Healthy, Renal Impairment
Interventions
quinine sulfate
Drug
Lead sponsor
Mutual Pharmaceutical Company, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
5 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2011
U.S. locations
1
States / cities
Miami Gardens, Florida
Source: ClinicalTrials.gov public record
Updated Jul 31, 2012 · Synced Sep 3, 2026, 7:30 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Investigation of the Effects of Renal Impairment on the Pharmacokinetics, Safety, and Tolerability of Opemalirsen (AZD2373)

NCT07154901
View directory record Official record
Conditions
Renal Impairment
Interventions
Opemalirsen (AZD2373)
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 80 Years
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
2
States / cities
Miami, Florida • Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Jun 25, 2026 · Synced Sep 3, 2026, 7:30 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of the Pharmacokinetics and Safety of BMS-663068 Administered in Subjects With Normal Renal Function and With Mild, Moderate, Severe and End Stage Renal Dysfunction (ESRD)

NCT02674581
View directory record Official record
Conditions
HIV Infections
Interventions
Oral BMS-663068 (pro-drug)
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated May 14, 2018 · Synced Sep 3, 2026, 7:30 AM EDT